PERNIX THERAPEUTICS HLDGS IN's ticker is PTX and the CUSIP is 71426V108. A total of 43 filers reported holding PERNIX THERAPEUTICS HLDGS IN in Q4 2013. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $1,002,000 | +215.1% | 1,610,542 | +126.7% | 0.00% | – |
| Q2 2016 | $318,000 | -80.0% | 710,276 | -53.2% | 0.00% | – |
| Q1 2016 | $1,592,000 | -58.2% | 1,516,585 | +17.5% | 0.00% | -100.0% |
| Q4 2015 | $3,807,000 | +6.5% | 1,290,434 | +14.1% | 0.00% | 0.0% |
| Q3 2015 | $3,574,000 | -45.2% | 1,131,074 | +2.7% | 0.00% | 0.0% |
| Q2 2015 | $6,522,000 | -41.5% | 1,101,650 | +5.7% | 0.00% | -50.0% |
| Q1 2015 | $11,141,000 | +22.0% | 1,042,145 | +7.1% | 0.00% | +100.0% |
| Q4 2014 | $9,133,000 | +25.8% | 972,614 | +2.9% | 0.00% | 0.0% |
| Q3 2014 | $7,260,000 | -1.1% | 945,252 | +15.6% | 0.00% | 0.0% |
| Q2 2014 | $7,342,000 | +146.2% | 817,561 | +46.7% | 0.00% | 0.0% |
| Q1 2014 | $2,982,000 | +149.1% | 557,391 | +17.4% | 0.00% | – |
| Q4 2013 | $1,197,000 | +12.7% | 474,933 | +21.6% | 0.00% | – |
| Q3 2013 | $1,062,000 | -21.0% | 390,541 | +4.9% | 0.00% | – |
| Q2 2013 | $1,344,000 | – | 372,224 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 4,800,000 | $15,168,000 | 5.18% |
| Avoro Capital Advisors LLC | 6,004,564 | $18,974,000 | 4.93% |
| DG Capital Management, LLC | 695,808 | $2,199,000 | 2.56% |
| ACUTA CAPITAL PARTNERS, LLC | 1,108,719 | $3,504,000 | 2.03% |
| Aisling Capital LLC | 2,010,000 | $6,352,000 | 1.12% |
| Broadfin Capital, LLC | 6,090,829 | $19,247,000 | 1.07% |
| KOPP INVESTMENT ADVISORS LLC | 375,293 | $1,186,000 | 0.64% |
| SEARLE & CO. | 172,500 | $545,000 | 0.56% |
| Elk Creek Partners, LLC | 1,864,515 | $5,892,000 | 0.48% |
| WALL STREET ASSOCIATES | 696,300 | $2,200,000 | 0.42% |